A recent study by Tumeh et al. found that preexisting CD8+ T cells are essential for tumor regression following therapeutic PD-1/PD-L1 blockade in metastatic melanoma, indicating that CD8+ TILs play a key role in anti PD-1 therapy response [56]. This evidence concerns the gene CD8A and metastatic melanoma.